ArticlePatient preference and adherence2026
Patient Preferences for Treatment in Relapsed/Refractory Acute Leukemia: A Multinational Discrete Choice Experiment.
Article in Patient preference and adherence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Acute leukemia (AL) is an aggressive cancer of white blood cells that progresses rapidly and requires intensive treatment. While first-line therapies can induce remission, this is not the case for all patients (refractory disease), and many patients experience a relapse. In these situations, treatment decisions become complex due to trade-offs between efficacy, toxicity and quality of life. Despite recognition of the importance of patient preferences in treatment decision-making, limited evidence exists on how individuals with AL value different treatment features. Patients and Methods: A web-based discrete choice experiment (DCE) was conducted across the UK, USA, France, Germany and Italy to quantify treatment preferences among adults with AL. Attributes were identified through literature review, formative qualitative research and patient input. Each participant completed 12 choice tasks comparing hypothetical treatment profiles varying by chance of response, duration of response, quality of life during treatment and response and mode of administration. Data were analyzed using mixed logit and latent class models to estimate conditional relative attribute importance (RAI) scores, explore preference heterogeneity and assess trade-offs. Results: A total of 267 respondents completed the study. Across the full sample, the chance of response was the most influential treatment attribute (RAI=62%), followed by quality of life during response (14%), duration of response (9%), quality of life during treatment (8%) and mode of administration (7%). Three latent preference classes were identified: efficacy-focused (47%), convenience- and efficacy-focused (21%) and balanced decision-makers (32%). Respondents in the USA were more likely to belong to the convenience- and efficacy-focused group, suggesting that contextual factors influence preferences. Conclusion: Patients with AL largely prioritize treatment efficacy but also value quality of life and convenience, indicating that treatment decisions are multifaceted and context dependent. Incorporating patient preferences into clinical development and health technology assessment can promote more person-centered approaches to care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.